{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:49:46Z","timestamp":1793396986612,"version":"4.5.0"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lfs.2024.123125","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:26:44Z","timestamp":1728988004000},"page":"123125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"special_numbering":"C","title":["Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors"],"prefix":"10.1016","volume":"358","author":[{"given":"Olusola","family":"Sogbein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradipta","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Chaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vecihi","family":"Batuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.123125_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","article-title":"The ubiquitin-proteasome proteolytic pathway","volume":"79","author":"Ciechanover","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123125_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.ge.26.120192.001143","article-title":"The ubiquitin-conjugation system","volume":"26","author":"Jentsch","year":"1992","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.lfs.2024.123125_bb0015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123125_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","article-title":"The effects of proteasome inhibitors on bone remodeling in multiple myeloma","volume":"86","author":"Zangari","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.lfs.2024.123125_bb0025","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.leukres.2008.02.019","article-title":"Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions","volume":"32","author":"Boissy","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.intimp.2017.06.009","article-title":"A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity","volume":"50","author":"Eleftheriadis","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00467-016-3319-3","article-title":"Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection","volume":"31","author":"Pearl","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.lfs.2024.123125_bb0040","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","article-title":"Bortezomib, tacrolimus, and metho-trexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors","volume":"114","author":"Koreth","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.neulet.2006.01.015","article-title":"The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia","volume":"398","author":"Henninger","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.lfs.2024.123125_bb0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/17425255.4.5.639","article-title":"Bortezomib in multiple myeloma","volume":"4","author":"Terpos","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.lfs.2024.123125_bb0055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp070272","article-title":"Bortezomib: a novel chemotherapeutic agent for hematologic malignancies","volume":"65","author":"Utecht","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.lfs.2024.123125_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2024.123125_bb0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Investig."},{"key":"10.1016\/j.lfs.2024.123125_bb0070","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0075","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/MCB.18.6.3509","article-title":"Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase","volume":"18","author":"Srivastava","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0080","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cbin.10259","article-title":"CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2\/Bax family proteins during treatment with microtubule interfering agents","volume":"38","author":"Zhou","year":"2014","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.lfs.2024.123125_bb0085","first-page":"45","article-title":"Equations of motion of spinning relativistic particle in electromagnetic and gravitational fields","volume":"3","author":"Khriplovich","year":"1998","journal-title":"Why We Need the Journal of Interactive Advertising"},{"key":"10.1016\/j.lfs.2024.123125_bb0090","first-page":"130","article-title":"Raf-1\/bcl-2 phosphorylation: a step from microtubule damage to cell death","volume":"57","author":"Blagosklonny","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0095","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1073\/pnas.96.7.3775","article-title":"Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis","volume":"96","author":"Srivastava","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2024.123125_bb0100","first-page":"229","article-title":"Bcl2 is the guardian of microtubule integrity","volume":"57","author":"Haldar","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2024.123125_bb0110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1242\/jcs.091777","article-title":"HECT and RING finger families of E3 ubiquitin ligases at a glance","volume":"125","author":"Metzger","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.lfs.2024.123125_bb0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrm2690","article-title":"Physiological functions of the HECT family of ubiquitin ligases","volume":"10","author":"Rotin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","article-title":"RING domain E3 ubiquitin ligases","volume":"78","author":"Deshaies","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.lfs.2024.123125_bb0125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02705243","article-title":"The ubiquitin-proteasome system","volume":"31","author":"Nandi","year":"2006","journal-title":"J. Biosci."},{"key":"10.1016\/j.lfs.2024.123125_bb0130","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(17)37345-3","article-title":"Distinct 19 S and 20 S subcom- plexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm","volume":"269","author":"Peters","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123125_bb0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/med.20111","article-title":"Proteasome inhibitors: poisons and remedies","volume":"28","author":"Meiners","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.lfs.2024.123125_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrm1336","article-title":"Proteasomes and their kin: proteases in the machine age","volume":"5","author":"Pickart","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2024.123125_bb0155","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1200\/JCO.2005.05.081","article-title":"The ubiquitin-proteasome pathway and its role in cancer","volume":"23","author":"Mani","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1073\/pnas.88.1.139","article-title":"Degradation of nuclear oncoproteins by the ubiquitin system in vitro","volume":"88","author":"Ciechanover","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2024.123125_bb0165","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200969070-00006","article-title":"Bortezomib: a review of its use in patients with multiple myeloma","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.123125_bb0175","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.084376","article-title":"Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.lfs.2024.123125_bb0180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2024.123125_bb0185","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123125_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/or.2022.10568","article-title":"NF-\u03baB signaling in tumor pathways focusing on breast and ovarian cancer","volume":"16","author":"Devanaboyina","year":"2022","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.lfs.2024.123125_bb0205","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr3175","article-title":"CIP2A is a target of bortezomib in human triple negative breast cancer cells","volume":"14","author":"Tseng","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0210","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1039\/D3BM00254C","article-title":"Bortezomib-loaded mixed micelles realize a \u201cthree-in-one\u201d effect for enhanced breast cancer treatment","volume":"11","author":"Liu","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.lfs.2024.123125_bb0215","first-page":"835","article-title":"Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts","volume":"2","author":"Williams","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb0220","article-title":"The role of proteasomes in tumorigenesis","volume":"11","author":"Zhou","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.lfs.2024.123125_bb0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.31083\/j.fbl2903106","article-title":"Cisplatin disrupts proteasome bounce-back effect through suppressing ZEB1\/Nfe2l1 in cholangiocarcinoma","volume":"29","author":"Xiang","year":"2024","journal-title":"Frontiers in Bioscience-Landmark"},{"key":"10.1016\/j.lfs.2024.123125_bb0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt.10.9","article-title":"Drug-mediated and cellular immunotherapy in multiple myeloma","volume":"2","author":"Ritchie","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2024.123125_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153778","article-title":"Targeting protein degradation pathways in tumors: focusing on their role in hematological malignancies","volume":"14","author":"Wolska-Washer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.123125_bb0240","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2024.123125_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/14796694.4.2.149","article-title":"Bortezomib in mantle cell lymphoma","volume":"4","author":"Suh","year":"2008","journal-title":"Future Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0250","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","article-title":"Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132","volume":"66","author":"Crawford","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0255","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920310791824057","article-title":"The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention","volume":"11","author":"Chen","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.lfs.2024.123125_bb0260","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1101\/gad.7.11.2063","article-title":"Proposed NF-kappa B\/I kappa B family nomenclature","volume":"7","author":"Nabel","year":"1993","journal-title":"Genes Dev."},{"key":"10.1016\/j.lfs.2024.123125_bb0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/373303a0","article-title":"Structure of NF-\u03baB p50 homodimer bound to a \u03baB site","volume":"373","author":"Ghosh","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123125_bb0270","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1128\/MCB.17.7.3629","article-title":"Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth","volume":"17","author":"Nakshatri","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00345-007-0175-6","article-title":"The NF-kappaB\/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?","volume":"25","author":"Paule","year":"2007","journal-title":"World. J. Urol."},{"key":"10.1016\/j.lfs.2024.123125_bb0280","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1541-7786.MCR-07-0309","article-title":"Host nuclear factor-kappaB activation potentiates lung cancer metastasis","volume":"6","author":"Stathopoulos","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0285","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2362.2007.01801.x","article-title":"NF-kappaB and apoptosis in colorectal tumourigenesis","volume":"37","author":"Aranha","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.lfs.2024.123125_bb0290","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","article-title":"The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2024.123125_bb0300","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/847373","article-title":"Protea- some inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis","volume":"2015","author":"Hsu","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.lfs.2024.123125_bb0305","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3892\/mmr.2017.6524","article-title":"Bortezomib protects against dextran sulfate sodium-induced ulcerative colitis in mice","volume":"15","author":"Hu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2024.123125_bb0310","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","article-title":"The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines","volume":"67","author":"Strauss","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0315","doi-asserted-by":"crossref","first-page":"32439","DOI":"10.18632\/oncotarget.5857","article-title":"Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-\u03baB crosstalk","volume":"6","author":"Thounaojam","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2024.123125_bb0320","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm0697-614","article-title":"The proto-oncogene Bcl-2 and its role in regulating apoptosis","volume":"3","author":"Kroemer","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.123125_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.27","article-title":"Bcl-2-regulated cell death signalling in the prevention of autoimmunity","volume":"1","author":"Tischner","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2024.123125_bb0330","first-page":"9","article-title":"Bcl-2 family-regulated apoptosis in health and disease","volume":"2","author":"Dewson","year":"2010","journal-title":"Cell Health Cytoskelet"},{"key":"10.1016\/j.lfs.2024.123125_bb0335","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Tait, targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0340","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0345","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.lfs.2024.123125_bb0350","doi-asserted-by":"crossref","first-page":"18984","DOI":"10.1074\/jbc.273.30.18984","article-title":"Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis","volume":"273","author":"Ling","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb0355","first-page":"841","article-title":"PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb0360","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1128\/jvi.64.10.4632-4639.1990","article-title":"Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13-acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line","volume":"64","author":"Hijikata","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2024.123125_bb0365","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.lfs.2024.123125_bb0370","doi-asserted-by":"crossref","first-page":"14557","DOI":"10.1038\/srep14557","article-title":"Structural mechanism for regulation of Bcl-2 protein Noxa by phosphorylation","volume":"5","author":"Karim","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.123125_bb0375","doi-asserted-by":"crossref","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","article-title":"Noxa\/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells","volume":"286","author":"Smith","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb0380","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0385","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0390","series-title":"Critical Roles of Noxa and Mcl-1 in the Signaling Mechanisms of Bortezomib in TRAF3-Deficient Mouse B Lymphoma and Human Multiple Myeloma Cells","author":"Luo","year":"2016"},{"key":"10.1016\/j.lfs.2024.123125_bb0395","series-title":"Human Molecular Genetics 2","author":"Strachan","year":"1999"},{"key":"10.1016\/j.lfs.2024.123125_bb0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.lfs.2024.123125_bb0405","first-page":"2961","article-title":"Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent","volume":"29","author":"Vaziri","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0410","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.1074\/jbc.272.20.12893","article-title":"p53-dependent induction of apoptosis by proteasome inhibitors","volume":"272","author":"Lopes","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb0415","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-05-0222","article-title":"Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin","volume":"4","author":"Vaziri","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb0420","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines","volume":"9","author":"Ling","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature02451","article-title":"Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms","volume":"429","author":"Saleh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123125_bb0430","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/cdd.2014.216","article-title":"Old, new and emerging functions of caspases","volume":"22","author":"Shalini","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lfs.2024.123125_bb0435","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.5-5-435","article-title":"The molecular perspective: caspases","volume":"5","author":"Goodsell","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.lfs.2024.123125_bb0440","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1038\/onc.2008.297","article-title":"Caspases in apoptosis and beyond","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2024.123125_bb0445","first-page":"1243","article-title":"Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts","volume":"1","author":"Nawrocki","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb0450","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2024.123125_bb0455","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cellsig.2012.10.004","article-title":"Bortezomib\/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells","volume":"25","author":"Selimovic","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.lfs.2024.123125_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-016-0823-y","article-title":"Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells","volume":"14","author":"Iskandarani","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2024.123125_bb0465","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1021\/acs.chemrev.5b00407","article-title":"Superoxide ion: generation and chemical implications","volume":"116","author":"Hayyan","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.lfs.2024.123125_bb0470","first-page":"794","article-title":"Free radicals and antioxidants in human health: current status and future prospects","volume":"52","author":"Devasagayam","year":"2004","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.lfs.2024.123125_bb0475","first-page":"vii","article-title":"Sustaining life on planet earth: metallo-enzymes mastering dioxygen and other chewy gases., met ions","volume":"15","author":"Kroneck","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2024.123125_bb0480","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive oxygen species in cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0485","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","article-title":"The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib","volume":"295","author":"Yu","year":"2004","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0490","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/sj.leu.2403109","article-title":"The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells","volume":"17","author":"Pei","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2024.123125_bb0495","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e1n","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0500","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.lfs.2024.123125_bb0505","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1073\/pnas.93.5.2002","article-title":"Antiangiogenic therapy of transgenic mice impairs de novo tumor growth","volume":"93","author":"Parangi","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2024.123125_bb0510","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0515","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cancers12041047","article-title":"Current approaches for combination therapy of cancer: the role of Immuno- genic cell death","volume":"12","author":"Asadzadeh","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.123125_bb0520","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0525","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s12035-018-1182-x","article-title":"Arginylated calreticulin increases apoptotic response induced by bortezomib in glioma cells","volume":"56","author":"Comba","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2024.123125_bb0530","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2024.123125_bb0535","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0540","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0545","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/jnci\/djn113","article-title":"Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody","volume":"100","author":"Shanker","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2024.123125_bb0550","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.lfs.2024.123125_bb0555","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.molimm.2010.05.003","article-title":"The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells","volume":"47","author":"Feng","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.lfs.2024.123125_bb0560","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0092-8674(04)00451-9","article-title":"Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells","volume":"117","author":"Amsen","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123125_bb0565","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0570","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.4049\/jimmunol.1103826","article-title":"Immune mechanism of the antitumor effects generated by bortezomib","volume":"189","author":"Chang","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2024.123125_bb0575","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0580","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2008.03818.x","article-title":"Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition","volume":"155","author":"Ames","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.lfs.2024.123125_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010085","article-title":"Bortezomib augments natural killer cell targeting of stem-like tumor cells","volume":"11","author":"Luna","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.123125_bb0590","article-title":"Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma","volume":"69","author":"Luczkowska","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0595","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management","volume":"90","author":"Watson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2024.123125_bb0600","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2015","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0610","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.lfs.2024.123125_bb0615","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Al\u00e9","year":"2015","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0620","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/0300985809358423","article-title":"Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro","volume":"47","author":"Csizmadia","year":"2010","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.lfs.2024.123125_bb0625","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.lfs.2024.123125_bb0630","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/ bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0635","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.lfs.2024.123125_bb0640","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbi.2015.11.004","article-title":"Upregulation of CCL2 via ATF3\/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy","volume":"53","author":"Liu","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.lfs.2024.123125_bb0645","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1568009618666181003170027","article-title":"The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy","volume":"19","author":"Yin","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2024.123125_bb0650","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12624","article-title":"Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma","volume":"164","author":"Azoulay","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0655","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1523\/JNEUROSCI.3030-10.2010","article-title":"MicroRNA loss enhances learning and memory in mice","volume":"30","author":"Konopka","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123125_bb0660","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1007\/s13277-015-3600-2","article-title":"Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma","volume":"36","author":"Peng","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lfs.2024.123125_bb0665","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood.V114.22.4918.4918","article-title":"miRNA expression in multiple myeloma as predictive model of response to bortezomib","volume":"114","author":"Neri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0670","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3109\/10428194.2011.591004","article-title":"Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation","volume":"52","author":"Wang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0675","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2443.2012.01611.x","article-title":"Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib","volume":"17","author":"Uyama","year":"2012","journal-title":"Genes Cells"},{"key":"10.1016\/j.lfs.2024.123125_bb0680","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hon.2391","article-title":"Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients","volume":"36","author":"Campo","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0685","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919850043","article-title":"Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy","volume":"15","author":"Ludman","year":"2019","journal-title":"Mol. Pain"},{"key":"10.1016\/j.lfs.2024.123125_bb0690","doi-asserted-by":"crossref","unstructured":"K.C. Anderson, S. Jagannath, A. Jakubowiak, S. Lonial, N. Raje, M. Alsina, I. Ghobrial, R. Knight, D. Esseltine, P. Richardson, Lenalidomide, Bortezomib, and Dexamethasone in Relapsed\/Refractory Multiple Myeloma (MM): Encouraging Outcomes and Tolerability in a Phase II Study, Doi:https:\/\/doi.org\/10.1200\/Jco.2009.27.15_suppl.8536 27 (2009) 8536\u20138536.","DOI":"10.1200\/jco.2009.27.15_suppl.8536"},{"key":"10.1016\/j.lfs.2024.123125_bb0695","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.14754","article-title":"Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0700","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal toxicities of novel agents used for treatment of multiple myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2024.123125_bb0705","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfv222","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.lfs.2024.123125_bb0710","series-title":"Pocket Medicine\u00a0: The Massachusetts General Hospital Handbook of Internal Medicine","author":"Sabatine","year":"2017"},{"key":"10.1016\/j.lfs.2024.123125_bb0715","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12185-008-0140-1","article-title":"Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma","volume":"88","author":"Morita","year":"2008","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0720","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","article-title":"Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib","volume":"41","author":"Moore","year":"2011","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.lfs.2024.123125_bb0725","article-title":"Bortezomib-induced thrombotic thrombocytopaenic purpura","volume":"2012","author":"Mehta","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.lfs.2024.123125_bb0730","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2014.977887","article-title":"Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma","volume":"56","author":"Chan","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0735","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2024.123125_bb0740","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2221-1691(12)60078-1","article-title":"Antimicrobial potential of Actinomycetes species isolated from marine environment","volume":"2","author":"Valli","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.lfs.2024.123125_bb0745","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.lfs.2024.123125_bb0750","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0755","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0760","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/ MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2024.123125_bb0765","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","article-title":"An overview of the role of carfilzomib in the treatment of multiple myeloma","volume":"18","author":"Ziogas","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.lfs.2024.123125_bb0770","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling","volume":"2015","author":"Accardi","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2024.123125_bb0775","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/2040620716667275","article-title":"A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma","volume":"7","author":"Franken","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.lfs.2024.123125_bb0780","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0785","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0790","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.lfs.2024.123125_bb0795","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0800","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123125_bb0805","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0810","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13296","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0815","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0820","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0825","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0830","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0835","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0840","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: first global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.123125_bb0845","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/10428194.2018.1523398","article-title":"Ixazomib - the first oral proteasome inhibitor","volume":"60","author":"Xie","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0850","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb0855","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0865","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bcp.12991","article-title":"Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment","volume":"82","author":"Gupta","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0870","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jcph.719","article-title":"The effect of a high-fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma","volume":"56","author":"Gupta","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0875","unstructured":"Highlights of Prescribing Information, (n.d.)."},{"key":"10.1016\/j.lfs.2024.123125_bb0880","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12542","article-title":"Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis","volume":"79","author":"Gupta","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0885","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-015-2815-7","article-title":"Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients","volume":"76","author":"Gupta","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123125_bb0890","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2024.123125_bb0895","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123125_bb0900","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0905","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41375-018-0038-8","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2024.123125_bb0910","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.15679","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexametha- sone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0915","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood.V128.22.3335.3335","article-title":"Ixazomib, thalidomide and dexamethasone (IxaThalDex) in relapsed\/refractory multiple myeloma (RRMM): an interim analysis of a phase II trial","volume":"128","author":"Ludwig","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0920","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","article-title":"Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0925","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/jpet.110.177824","article-title":"Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs","volume":"337","author":"Obaidat","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb0930","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.lfs.2024.123125_bb0935","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/md8040835","article-title":"Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides","volume":"8","author":"Potts","year":"2010","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.lfs.2024.123125_bb0940","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1021\/jo100432g","article-title":"Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy","volume":"75","author":"Ling","year":"2010","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb0945","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1039\/c0cc00607f","article-title":"A(1,3)-strain enabled retention of chirality during bis-cyclization of beta-ketoamides: total synthesis of (-)-salinosporamide A and (-)-homosalinosporamide A","volume":"46","author":"Nguyen","year":"2010","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.lfs.2024.123125_bb0950","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2024.123125_bb0955","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2024.123125_bb0960","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2024.123125_bb0965","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0970","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V118.21.302.302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0975","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb0980","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/jco.2009.27.15_suppl.3516","article-title":"First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052","volume":"27","author":"Hamlin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.123125_bb0985","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/156800911794519725","article-title":"Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs)","volume":"11","author":"Kuhn","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2024.123125_bb0990","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb0995","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb1000","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Zang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123125_bb1005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2017.03.002","article-title":"Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and\/or dexamethasone (Dex)","volume":"57","author":"Sanchez","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lfs.2024.123125_bb1010","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/dmd.117.075226","article-title":"In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s","volume":"45","author":"Wang","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lfs.2024.123125_bb1015","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4161\/cbt.29452","article-title":"Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors","volume":"15","author":"Zang","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2024.123125_bb1020","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.123125_bb1025","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm7010589","article-title":"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer","volume":"51","author":"Dorsey","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123125_bb1030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lfs.2024.123125_bb1035","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2024.123125_bb1040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2024.123125_bb1045","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","article-title":"Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma","volume":"58","author":"Vogl","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.lfs.2024.123125_bb1050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.lfs.2024.123125_bb1055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3892\/etm.2015.2617","article-title":"Bortezomib inhibits cell proliferation in prostate cancer","volume":"10","author":"Zheng","year":"2015","journal-title":"Exp. Ther. Med."},{"issue":"21","key":"10.1016\/j.lfs.2024.123125_bb1060","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V116.21.1813.1813","article-title":"Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400715X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400715X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:38:11Z","timestamp":1736185091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052400715X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":209,"alternative-id":["S002432052400715X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123125","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123125"}}